DrugPatentWatch Database Preview
Celgene Company Profile
Email this page to a colleague
What is the competitive landscape for CELGENE, and what generic alternatives to CELGENE drugs are available?
CELGENE has eight approved drugs.
There are thirty-five US patents protecting CELGENE drugs.
There are six hundred and ninety-one patent family members on CELGENE drugs in fifty countries and thirty-seven supplementary protection certificates in sixteen countries.
Summary for Celgene
| International Patents: | 691 |
| US Patents: | 35 |
| Tradenames: | 8 |
| Ingredients: | 7 |
| NDAs: | 8 |
| Patent Litigation for Celgene: | See patent lawsuits for Celgene |
| PTAB Cases with Celgene as patent owner: | See PTAB cases with Celgene as patent owner |
Drugs and US Patents for Celgene
Expired US Patents for Celgene
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Celgene | THALOMID | thalidomide | CAPSULE;ORAL | 020785-002 | Jan 17, 2003 | 6,908,432 | ⤷ Sign up for a Free Trial |
| Celgene | POMALYST | pomalidomide | CAPSULE;ORAL | 204026-004 | Feb 8, 2013 | 6,755,784 | ⤷ Sign up for a Free Trial |
| Celgene | THALOMID | thalidomide | CAPSULE;ORAL | 020785-004 | Jan 10, 2007 | 5,629,327 | ⤷ Sign up for a Free Trial |
| Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-005 | Dec 21, 2011 | 6,281,230 | ⤷ Sign up for a Free Trial |
| Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-006 | Jun 5, 2013 | 6,561,976 | ⤷ Sign up for a Free Trial |
| Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-002 | Dec 27, 2005 | 5,635,517 | ⤷ Sign up for a Free Trial |
| Celgene | REVLIMID | lenalidomide | CAPSULE;ORAL | 021880-003 | Jun 29, 2006 | 8,204,763 | ⤷ Sign up for a Free Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for CELGENE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 1 mg, 2 mg, 3 mg and 4 mg | ➤ Subscribe | 2017-02-08 |
| ➤ Subscribe | Capsules | 5 mg, 10 mg and 15 mg | ➤ Subscribe | 2010-08-30 |
| ➤ Subscribe | Capsules | 50 mg and 100 mg | ➤ Subscribe | 2006-12-18 |
| ➤ Subscribe | Capsules | 150 mg | ➤ Subscribe | 2014-02-03 |
| ➤ Subscribe | Capsules | 25 mg | ➤ Subscribe | 2010-07-12 |
| ➤ Subscribe | Capsules | 2.5 mg and 20 mg | ➤ Subscribe | 2016-07-12 |
| ➤ Subscribe | Capsules | 200 mg | ➤ Subscribe | 2006-09-25 |
| ➤ Subscribe | Injection | 10 mg/vial | ➤ Subscribe | 2013-11-05 |
International Patents for Celgene Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Eurasian Patent Organization | 201290331 | ⤷ Sign up for a Free Trial |
| Ecuador | SP066467 | ⤷ Sign up for a Free Trial |
| World Intellectual Property Organization (WIPO) | 2011143147 | ⤷ Sign up for a Free Trial |
| Eurasian Patent Organization | 021672 | ⤷ Sign up for a Free Trial |
| Argentina | 047994 | ⤷ Sign up for a Free Trial |
| South Korea | 101752124 | ⤷ Sign up for a Free Trial |
| China | 1738607 | ⤷ Sign up for a Free Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Celgene Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2105135 | 92642 | Luxembourg | ⤷ Sign up for a Free Trial | PRODUCT NAME: POMALIDOMIDE ET SES SELS, SOLVATES, HYDRATES OU STEREOISOMERES PHARMACEUTIQUEMENT ACCEPTABLES QUI EN DERIVENT (IMNOVID); FIRST REGISTRATION DATE: 20130805 |
| 2105135 | 5/2015 | Austria | ⤷ Sign up for a Free Trial | PRODUCT NAME: POMALIDOMID UND SEINE PHARMAZEUTISCH AKZEPTABLEN SALZE, SOLVATE, HYDRATE ODER STEREOISOMERE; REGISTRATION NO/DATE: EU/1/13/850 20130805 |
| 0688211 | SPC/GB08/039 | United Kingdom | ⤷ Sign up for a Free Trial | PRODUCT NAME: THALIDOMIDE (INTERNATIONAL NON-PROPRIETARY NAME) 2-(2,6-DIOXOPIPERIDIN-3-YL) ISOINDOLINE-1,3-DIONE (SYSTEMATIC (IUPAC) NAME); REGISTERED: UK EU/1/08/443/001 20080416 |
| 2498610 | 2090047-8 | Sweden | ⤷ Sign up for a Free Trial | PRODUCT NAME: OZANIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR OZANIMOD HYDROCHLORIDE; REG. NO/DATE: EU/1/20/1442 20200525 |
| 2291080 | C202030049 | Spain | ⤷ Sign up for a Free Trial | PRODUCT NAME: OZANIMOD O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR CLORHIDRATO DE OZANIMOD; NATIONAL AUTHORISATION NUMBER: EU/1/20/1442; DATE OF AUTHORISATION: 20200520; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1442; DATE OF FIRST AUTHORISATION IN EEA: 20200520 |
| 2291080 | PA2020529 | Lithuania | ⤷ Sign up for a Free Trial | PRODUCT NAME: OZANIMODAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, YPAC OZANIMODO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/20/1442 20200520 |
| 2105135 | 1590004-6 | Sweden | ⤷ Sign up for a Free Trial | PRODUCT NAME: POMALIDOMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS, SOLVATES, HYDRATES OR STEREOISOMERS THEREOF; REG. NO/DATE: EU/1/13/850 20130808 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
